The local ecosystem thrives because experts from institutions like Harvard, Biogen, and MGH continually join forces to create new ventures, leveraging a shared pool of specialized knowledge and experience from established players.
Biotech CEOs with business-only backgrounds often possess a crucial humility about their scientific limitations. This forces them to prioritize hiring exceptional R&D talent and empowering them to succeed, avoiding the trap of micromanagement.
When a biotech company shutters, it's not a total loss. The scientific dead ends it uncovers prevent others from wasting resources on the same path. These "failures" enrich the ecosystem with crucial knowledge and release experienced talent back into the market.
In talent-dense ecosystems like Massachusetts, CEOs must deliberately craft and brand their company culture to stand out and compete for top-tier scientists and executives. Simple things like team nicknames become part of this strategic branding.
Policies that cap prices on oral medications (the "pill penalty") warp investment incentives. Venture capitalists may stop funding companies developing pills, meaning promising academic research for these therapies might never be commercialized for patients.
A new CEO's initial plans are inherently flawed because they're based on an external perception. The first priority should be to listen to all stakeholders to build trust and gain a true understanding of the company's internal reality before setting a strategy.
The US regulatory regime for early clinical trials is so slow that companies are opting for more efficient systems, like Australia's local IRB-based approval. This offshoring of initial research puts the US at a global competitive disadvantage in generating crucial early data.